Trending Topic

3D Rendered Medical Illustration of Male Anatomy - Colon Cancer; Ascending Colon.
17 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of all pathogenic alterations and are the subject of extensive research in molecular and clinical oncology.1 The RAS family consists of three major isoforms, namely the Harvey rat sarcoma virus (HRAS), the neuroblastoma RAS […]

PART ONE: Nicholas Short, EHA 2022: Ponatinib and blinatumomab in patients with PH+ALL: Results of a phase II study

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 18th 2022

In Part One of this video interview, Prof Nicholas Short (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his phase II trial looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. A total of 55 patients were treated and the combination therapy showed complete molecular response. These data could present a potential paradigm shift in treatment options for Philadelphia chromosome-positive ALL.

Abstract: S114: ‘PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY’ was presented at the EHA annual meeting 2022.

Questions

  1. What are the challenges of treating Philadelphia chromosome-positive acute lymphoblastic leukaemia (PH+ALL) (00:14-01:10)
  2. What was the rationale for combined therapy with ponatinib and blinatumomab in patients with PH+ALL? (01:10-02:48)
  3. Which patients are most likely to benefit from this combined regimen? (03:15-04:20)

Disclosures: Nicholas Short is consultant for Pfizer Inc., Jazz Pharmaceuticals and Sanofi. He has received grant/research support from Takeda Oncology, Astellas Pharma Inc., Xencor and Stemline Therapeutics, and honoraria/honorarium from Novartis, Amgen and Sanofi.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the 27th Congress of the European Hematology Association (EHA).

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup